Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could happen in phase 2b results are good
Assuming they start it in 2015 we wont know until 2017 or later
Mcnally has always stated that big pharma will take this the rest of the way
Smells like capitulation today. Averaged down a little more at 50 cents
Thats for preclinical work. Not the 70 mil nih funding needed for phase 2b
Post facts and stop spinning
Stop feeding the troll guys this one is even dumber than colon hardon oh the yahoo mb
Exactly "some blogger" aka nobody wrote something
You and i can also write something. Doesnt make it true
If they dont get nih funding they are done
It sure looks like the approval was priced. However what is not priced in is the partnership or buyout and its terms.
Im all for pps going up but total bs conjecture from pumptards like you really annoys me. Especially with a name like otcpimp ur going on the ignore list
That dive was nothing. Should have seen dndn right before the halt. From 10 and change all the way down to 4. That was way more criminal than this.
I got in at 8.85. Im happy
Finally the bear raid i was expecting. Only 8.20 not as much as. I thought. Lol. And label isnt bad. Pretty much everything we expected and nothing like the bashers would have us believe
Think we gonna drift higher from here as we wait for the partnership announcement
Testing 10.60 now. Like u said we gonna make a go at 11 this week
Good volume today. Lets get past 10.60
Think thats risky. Still expecting a massive bear raid to take out stops when it gets close to the pdufa date. Better just to play with whatever money you have and not borrow
Yup anyone have any doubts should watch the entire adcom public hearing. Afrezza is a game changer
Gamb were u in dndn? Right before they halted trading for approval there was a massive bear raid that dropped the pps down to 4 and change. Think it was trading at around 10 too.
Gapped to 20 plus after fda decision.
Different stock. But could happen here too
Could be the shakeout of weak hands before next move up. Id buy more but all my money in mnkd.
Guess we gonna close the gap at 2.80 before we move up?
Any thoughts guys on when fda will release full hold?
Greed is just as powerful as fear
Im very long this stock but just hoping for a decent price to buy more shares. What im actually hoping for is a massive bear raid in the days leading up to july 15. Saw it happen in dndn 4 years ago and hoping it will happen here. Sucks for people with stop loss or those that bought on margin but Would be a good chance to load up.
What price point u looking to buy back? Im hoping for a pull back under 10. Not sure if it will happen.
Have they said anything about status for neopulse and eu approval yet? That could move pps higher same as a partnership
NCT01571960 estimated completion date september 2014
Possible catalyst once data is published. Completion date is also inline with projected trial for 2015. Could possibly further nih funding based on new data?
I doubt fauci over at nih will cut funding for one of the only phase 2b rdy vaccines in trials.
No short term catalysts Next trial isnt until 2015 for phase 2b
News of nih funding will definitely move share price
When govx ran up to .97 on no news. They repriced their warrants at .35 a share. That dropped the pps real fast lol
Trade. Its trading at current pps because their r no catalysts to drive pps higher at the moment.
The science is sound at least so far for phase 1 and 2a. But like any biotech. We all know those who show promising data early on can fail in expanded efficacy trials
That said i still do belief they have the most promising hiv vaccine in efficacy trial Lack of funding, internal politics at nih seem to be holding things up.
Its weird how all of a sudden they dropped govxb21 and hvtn forcing them to go with a protein boost
Something is up thats for sure. Whether its leaked trail data or buy out/merger news. Someone knows something and is driving share price up
Very good volume too. Things r looking goid
They should have a buy out or a partnership long before fda approval
What happened to merger with histogen? Guess histogen with a legitimate pipeline and clinical research found out what a scam this company was. Lol scam company merging with other scam companies in order to scam more money from unwitting investors
Seems no one is interested in this stock except u and jude lol
Why even debate this? this is nothing but a shell
Nothing to talk about until the reverse merger happens
Ice,
Any idea what happened with them before? They kind of just fell off the face the earth and stopped reporting. The tech is interesting. What happened to the company?
Personally i dont give a rats ass about this company in its current form. What i do care about is histogen and. Its research and ips. As someone who is suffering from male
Pattern baldness i have been following histogens progress for years and i be lieve the science works.
I will be putting money here if and when the merger is done and the dust from the reverse split settles.
Is histogen going to do a reverse merger here to go public?
("Bluesky" "BSKS" or the "Company") Dan Kehoe, CEO of BSKS, announced today that he will be resigning as CEO of the Company, as part of a comprehensive restructuring. The Company has assembled a Think Tank group, to be led by Dr. Alan E. Rand, to develop a new strategic financing plan and to bring up to date the Company’s SEC reporting requirements. Other members of the Think Tank will include six highly experienced individuals with impeccable credentials: Dr. John Hertz, Steven Antebi, Mark R. Moskowitz, Esq., Don Weiss, Gordon Romney and Andrew Seybold.
It is currently intended that the six individuals joining Dr. Rand will ultimately become members of a reconstituted Board of Directors. However, in each case, their willingness to do so will be subject, among other things, to the Company’s receipt of the amount of working capital determined by the Think Tank group as necessary to move forward, as well as the successful completion of the Think Tank’s tasks, including the completion of an approved business plan and of the necessary updating of the Company’s SEC reports.
Dr. Hertz, a licensed chiropractor for 30 years, has a thriving chiropractic practice in Los Angeles with a large and prominent clientele. A graduate of Western States Chiropractic College, he became Professor of Diagnosis, Bio Mechanics, and Director of Western States Clinic for Portland, Oregon, where he was in charge of 90 interns. Dr. Hertz also served as Director of the International Sports Medicine Institute in Los Angeles, and he is presently President of the Center for Spinal Diagnostics, Inc. Subject to the satisfaction of the conditions to his serving as a director, it is intended that Dr. Hertz will replace Mr. Kehoe as President of the Company.
Mr. Antebi, an experienced investor with a diverse portfolio, and a well known philanthropist in the Los Angeles area, is currently President and CEO of Maple Capital Management, and has an affiliation with Cedars Sinai Hospital, a major health care facility in the Los Angeles area. Also subject to satisfaction of the aforementioned conditions precedent, it is currently contemplated that he would serve as Chairman of the Board.
Mr. Moskowitz, a Harvard Law School graduate and a former Editor of the Harvard Law Review, has practiced corporate and securities law in Los Angeles for over 40 years for a number of major firms, representing a diverse client base, and is currently a member of the California Bar. Heis expected to serve as Secretary of the Company if the requisite funding is obtained if the tasks identified by the Think Tank are successfully completed.
Don Weiss another proposed Board member has had a diverse career in the worlds of micro and nano-technologies and investment banking. He founded and took public a successful company engaged in the design, manufacturing and marketing of Micro-Electro-Mechanical Systems, and ran that public company as its CEO for ten years. He went on to found and raise funding for another electronics company, and then joined Bell Labs Research (Lucent Technologies, now Alcatel-Lucent) as its Vice President of its Nanotechnology Consortium. Mr. Weiss created a new profit center at Bell Labs and he developed public and private funding to enable the commercialization of a wide range of Bell Labs technologies. These technologies typically had broad applications across both commercial and military markets. He worked closely with Bell Labs research scientists as well as all levels of management to monetize the Bell Labs technology portfolio (approximately 33,000 patents) by bidding, successfully for government-sponsored programs as well as finding venture capital and strategic partners to fund advanced technology research and development and commercialization of new products.
Gordon Romney, the fifth prospective board member, is currently focused on the development of a Master of Science program for Cyber Security and Information Assurance (MS CSIA) for National University in San Diego, California. This program is designed to help meet the critical need for 60,000 “Cyber Warriors” in the U.S. and globally, to confront the surging international attacks on internet and enterprise computer infrastructures. Mr. Romney is a full Professor at National University in the School of Engineering, Technology (2007-present) and in the Department of Computer Science, Information and Media Systems. Romney is the architect and initial lead faculty member for the MS in Cyber Security and Information Assurance (CSIA) program, and he is also theSenior Research Scientist in the Cyber Security Institute of San Diego.
Andrew Seybold, the final proposed Board member, is one of the world’s leading authorities on technology and trends shaping the world of wireless mobility. Mr. Seybold is a respected analyst, consultant, commentator, author, and active participant in wireless trade organizations. For more than forty years, he has served the industry and shaped initiatives for many of the world’s most respected names in the wireless industry including Verizon, Nokia, AT&T, Motorola, and Qualcomm. His firm has advised wireless companies from startups to Fortune 1000 companies, such as Dow Chemical, Ford Motor Company and Microsoft, and provides education services through its “Wireless” University” program.
The Company said all six of the named individuals have expressed their support for the Supera technology licensed by the Company, on an exclusive basis, for healthcare industry applications. On an interim basis, the proposed new officers and directors intend to work through the Think Tank on the development of a new business plan focused on the healthcare industry and the development and successful new bridge financing plan, both of which are among the aforementioned conditions precedent to the contemplated restructuring and the assumption by the named individuals of their new positions. Consummation of the necessary bridge financing will facilitate the development of new card prototypes utilizing the licensed Supera technology, which is a prerequisite to the establishment of advantageous manufacturing relationships. Such financing would also enable the Company to engage qualified certified public accountants to bring all financial statements and SEC reporting current.
While the proposed new officers and directors are currently optimistic that they will be able to accomplish their initial objectives, as well as to bring on additional experienced board members and officers if deemed beneficial, there can be no assurance that they will be successful, or that the contemplated restructuring will occur.
For any question, please call Mark R. Moskowitz at 310/456-5152.
Anyone know whats going on here?
Dilution?
They seem to have some good products and increasing albiet inconsistent revenue so why does the share price keep dropping? They diluting?
What does it mean for their 2nd gen theraputic vaccine if Impaact doesnt do the trial?
Whats up everyone, just bought in to atnp. Liked their products and research and their increasing revenue. Whats with the stock price though? Think this is the bottom or can this go down lower?
100 percent gain on no news and light volume. What is the story now with this stock. Didnt they have a lot of patents and was trying to bring their smart card to market? Last 8k was august of last year and nothing since then. Whats the new developments? Are they still in business? At least they are not bleeding cash and diluting the stock by issuing more shares os still shows 39 mil shares. No one selling and no one buying due to lack of interest